John Th. M. Plukker

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial

Joël Shapiro, J. Jan B. van Lanschot, Maarten C.C.M. Hulshof et al. · The Lancet Oncology · 2015 · 2.5K citations

Surgical Oncology, Neoadjuvant Chemoradiotherapy, Esophageal Cancer +9

Extended Lymph-Node Dissection for Gastric Cancer

Johannes J. Bonenkamp, J. Hermans, Mitsuru Sasako et al. · New England Journal of Medicine · 1999 · 1.6K citations · Full text

Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients

Johannes J. Bonenkamp, Ilfet Songun, K Welvaart et al. · The Lancet · 1995 · 1K citations

Surgical Oncology, D2 Dissection, Gastrointestinal Oncology +9

Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial

H.H. Hartgrink, C.J.H. van de Velde, Hein Putter et al. · Journal of Clinical Oncology · 2004 · 920 citations · Full text

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial

Ben M. Eyck, J. Jan B. van Lanschot, Maarten C.C.M. Hulshof et al. · Journal of Clinical Oncology · 2021 · 709 citations · Full text